Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

Author(s):

Giselle Mosnaim, MD, MS ,Shyam Joshi, MD

Panelists discuss how chronic spontaneous urticaria (CSU) treatment targets multiple pathways through antihistamines, anti-IgE therapy, and BTK inhibitors, with BTK emerging as a key target.

EP: 1.Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

EP: 2.Pathophysiology of Chronic Spontaneous Urticaria

Now Viewing

EP: 3.Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

Video content above is prompted by the following:

What mechanisms and targets are currently being utilized or studied for the treatment of CSU?
Why are so many patients (more than half) with CSU unable to achieve adequate control with antihistamines alone?
What role does BTK play in the pathogenesis of CSU?
BTK signaling is involved in pathways that lead to the degranulation of skin mast cells, which are key pathogenic drivers of CSU.
BTK also presents in B cells and basophils, the latter of which activate and degranulate similarly to mast cells.